Lung Cancers

New Targeted Therapies for Non-Small Cell Lung Cancer

The NCCN Guidelines® Non-Small Cell Lung Cancer are updated frequently throughout the year to include new approved agents and indications. It is difficult for clinicians to stay up-to-date on the most recent recommendations to improve outcomes for their patients with metastatic NSCLC. In addition, clinicians need to be aware of novel adverse reactions that may occur with the new targeted therapies.

NCCN Guidelines® Updates: Targeted Therapy for Patients with Metastatic Non-Small Cell Lung Cancer

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer

In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.

NCCN Guidelines® Insights - Lung Cancer Screening, Version 1.2025

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.

Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer

This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.

NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer

This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.

New Targeted Therapies for Metastatic Non-Small Cell Lung Cancer

Clinicians need to be aware of the most recent recommendations about biomarker testing and the appropriate use of new targeted therapies (including sequencing these therapies, assessing and managing side effects from these therapies), so they can select the most appropriate therapy for their patients with metastatic NSCLC.

Updates in the Management of Small Cell Lung Cancer

For many years, platinum plus etoposide regimens had been recommended for patients with extensive stage small cell lung cancer (SCLC); however, the preferred regimens for extensive stage SCLC now include immune checkpoint inhibitors, either atezolizumab or durvalumab, plus platinum plus etoposide.

Archived Monthly Oncology Tumor Boards: Management of Early-Stage Non-Small Cell Lung Cancer

Health care providers need to know about the recent updates to the NCCN Guidelines for Non-Small Cell Lung Cancer to provide the best care for their patients with NSCLC, including adverse reactions that may occur with use of the new neoadjuvant and adjuvant systemic therapy regimens.

Monthly Oncology Tumor Boards: Management of Early-Stage Non-Small Cell Lung Cancer